Matthew Becker Speaks With PharmaWire on the Potential Patent Life of BTC and Johnson & Johnson’s Abiraterone Drug For Prostate Cancer
November 29, 2010
PharmaWire reported on November 29, 2010 that the patent life of BTG and Johnson & Johnson’s potential prostate cancer blockbuster abiraterone is unclear due to laws changed in 1995 for calculating expiration dates. According to BTG, abiraterone is protected until 2024. Although abiraterone is a simple molecule that will be reproduced by generic companies very easily and the drug may have a short patent life relying on data exclusivity, experts believe the data is still striking enough to secure a large market share in this timeframe. The companies are expected to also file for an extension of the patent for up to five years. However, patents covering manufacturing and synthesis methods typically cannot be enforced against generic applicants until shortly prior to commercial launch, Matthew Becker, a patent attorney at Axinn, noted in the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating the Hart-Scott-Rodino Act in 2025
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
State by State, Pre-Merger Notifications Expand
Axinn Viewpoints
Antitrust
FTC claims diverging market from EU in Mars/Kellanova clearance
Media Mentions
Keeping an Eye on the Ball: America First Antitrust Weighs in on the “Uniquely American System of Scholar Athletics”
Axinn Viewpoints
Antitrust
Wait, We Have To Tell Who? What You Need To Know About State Premerger Notifications
Podcast
MBK | MSK Fellowship Summit 2025
Sponsorship
Antitrust